Alkyl-glycoside enhanced vaccination
AssigneeThe UAB Research Foundation
InventorsJohn Arnold, Chun-Ming Huang, Elias Meezan, Dennis Pillion, De-Chu Tang
Life of this patent
Estimating the term…
Abstract
Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.
Claims106
A method for increasing the penetration of a vaccine through the skin of a subject, comprising:
- (a) contacting the skin of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the skin of the subject with an effective amount of the vaccine,
- whereby the amount of vaccine that penetrates the skin of the subject is greater after step (b) when compared to the amount of vaccine that is absorbed in the absence of step (a).
A method for enhancing, inducing, or potentiating an immune response or a therapeutic response in a subject, comprising:
- (a) contacting skin cells of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the skin cells of the subject with an effective amount of a vaccine.
A method for increasing the penetration of a vaccine through a mucosal surface of a subject, comprising:
- (a) contacting the mucosal surface of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the mucosal surface of the subject with an effective amount of the vaccine,
- whereby the amount of vaccine that penetrates the mucosal surface of the subject is greater after step (b) when compared to the amount of vaccine that is absorbed in the absence of step (a), and wherein the contacting steps (a) and (b) are not performed by inhalation.
A method for enhancing, inducing, or potentiating an immune response or a therapeutic response in a subject, comprising:
- (a) contacting mucosal cells of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the mucosal cells of the subject with an effective amount of a vaccine,
- wherein the contacting steps (a) and (b) are not performed by inhalation.
A method for increasing the penetration of a vector through the mucosal surface of a subject, comprising:
- (a) contacting the mucosal surface of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the mucosal surface of the subject with an effective amount of the vector,
- whereby the amount of vector that penetrates the mucosal surface of the subject is greater after step (b) when compared to the amount of vector that is absorbed in the absence of step (a).
A method for enhancing an immune response in a subject, comprising
- (a) contacting the mucosal surface of the subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the mucosal surface of the subject with an effective amount of a vector,
- whereby the immune response is greater after step (b) when compared to the systemic immune response in the absence of step (a).
A method for inducing or potentiating a therapeutic response in a subject, comprising:
- (a) contacting the mucosal surface of a subject with an effective amount of an alkyl glycoside;
- and
- (b) contacting the mucosal surface of the subject with an effective amount of a vector,
- thereby inducing or potentiating the therapeutic response in the subject.
A composition comprising an alkyl glycoside and a vector.
A kit comprising an alkyl glycoside and a vector.
Dependencies are inferred from the claim text.